Abstract
A pretransplant test dose of i.v. BU was previously used in pediatric patients undergoing a reduced-intensity allogeneic hematopoietic SCT (HSCT). Here, we used a BU test dose in 23 adult patients who were not pancytopenic and underwent a myeloablative allogeneic HSCT prepared with fludarabine and i.v. BU (FluBU). Pharmacokinetics (PK) of BU were calculated after a test dose (0.8 mg/kg) was performed 2 weeks before transplant. Targeted BU area under the curve (AUC) range was 4800–5200 μM min. The mean BU dose calculated after the test dose was 3.5±0.5 mg/kg. To validate the test dose, PK studies were repeated in 17 patients after the first dose of BU during the conditioning regimen. An AUC below the therapeutic value of 4000 μM min was observed in 23% of the patients receiving a wt-based dose and in 0% of patients whose dose was calculated on the basis of the test dose (P=0.03). In patients who had a test dose, a significant correlation (P<0.0001) between the first and subsequent doses of BU during the conditioning regimen was observed. Our findings may allow more centers to pursue transplant strategies with targeted BU by overcoming the time limitation for PK studies during the conditioning regimen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820–826.
Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C . Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.
Anderson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS . Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548–554.
Fernandez HF, Tran HT, Federico A, Lennon S, Caldera H, Goodman MS . Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice daily or daily schedule to patients with advanced hematology malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486–492.
Madden T, De Lima M, Thapar N, Nguyen J, Roberson S, Couriel D . Pharmacokinetics of once daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6 h dosing schedule. Biol Blood Marrow Transplant 2007; 13: 56–64.
Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C . Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R . Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.
Kangarloo S, Naveed F, Anderson B . Individualized once daily dosing of intravenous Busulfan: a pharmacokinetic study in patients undergoing conditioning for allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; Tandem BMT meeting, Abstract no. 98.
Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ . Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154.
Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477–482.
Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/I.V. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935–940.
Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE . Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.
Kletzel M, Jacobsohn D, Duerst R . Pharmacokinetics of test dose of intravenous Busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous Busulfan in children undergoing a reduced intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 472–479.
Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H . Lorazepam for seizure prophylaxis during high-dose busulfan administration, Bone Marrow Transplant. 2002; 29: 963–965.
McCune JS, Gibbs JP, Slattery JT . Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155–165.
Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525–530.
Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150.
Li X, Ruiz CH, Koenig M, Cameron MD . Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways. Drug Metab Dispos 2009; 37: 1242–1250.
Russell JA, Kangarloo SB . Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008; 14: 1936–1949.
Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE . A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619–624.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beri, R., Chunduri, S., Sweiss, K. et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 45, 249–253 (2010). https://doi.org/10.1038/bmt.2009.133
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.133
Keywords
This article is cited by
-
Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
International Journal of Hematology (2021)
-
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality
Bone Marrow Transplantation (2019)
-
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients
Annals of Hematology (2018)
-
Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant
Bone Marrow Transplantation (2016)
-
Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients
International Journal of Hematology (2015)